Current evidence for the hepatoprotective activities of the medicinal mushroom Antrodia cinnamomea

Chinese Medicine (Impact Factor: 1.49). 11/2013; 8(1):21. DOI: 10.1186/1749-8546-8-21
Source: PubMed

ABSTRACT Antrodia cinnamomea (AC) is an endemic mushroom species of Taiwan, and has been demonstrated to possess diverse biological and pharmacological activities, such as anti-hypertension, anti-hyperlipidemia, anti-inflammation, anti-oxidation, anti-tumor, and immunomodulation. This review focuses on the inhibitory effects of AC on hepatitis, hepatocarcinoma, and alcohol-induced liver diseases (e.g., fatty liver, fibrosis). The relevant biochemical and molecular mechanisms are addressed. Overall, this review summarizes the hepatoprotective activities in vitro and in vivo. However, there is no doubt that human and clinical trials are still limited, and further studies are required for the development of AC-related products.

1 Follower
77 Reads
  • Seminars in Liver Disease 09/1981; 1(3):203-16. DOI:10.1055/s-2008-1041748 · 4.95 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Subpopulations of individuals with alcohol-induced fatty livers and nonalcoholic steatosis develop steatohepatitis. Steatohepatitis is defined histologically: increased numbers of injured and dying hepatocytes distinguish this condition from simple steatosis. The increased hepatocyte death is generally accompanied by hepatic accumulation of inflammatory cells and sometimes increases in myofibroblastic cells, leading to hepatic fibrosis and eventually, cirrhosis. The purpose of this review is to summarize similarities and differences in the pathogenesis of steatohepatitis in alcoholic fatty liver disease and nonalcoholic fatty liver disease.
    Seminars in Liver Disease 06/2009; 29(2):200-10. DOI:10.1055/s-0029-1214375 · 4.95 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The diversity of clinical syndromes and disease manifestations associated with HBV infection strongly suggests that the clinical outcome of this infection is determined by the quality and vigor of the antiviral immune response produced by the infected host. Antibodies to antigens expressed at the surface of virus particles can provide protection from initial infection and can prevent viral spread from cell to cell once infection is established. Antibody-mediated immune complex formation can contribute to extrahepatic syndromes in these patients and may even play a role in liver disease if they can bind to the surface of antigen-positive hepatocytes and recruit Fc receptor-positive killer cells, thereby mediating antibody dependent cellular cytotoxicity. CD4-positive helper T cells serve a critically important regulatory function by secreting a variety of cytokines that can facilitate B cell maturation, expansion, and antibody secretion or that foster the development of a strong CTL response. CD8-positive CTLs can kill infected cells by direct contact, triggering them to undergo apoptosis and recruiting antigen-nonspecific inflammatory cells that amplify their cytopathic potential. They also secrete cytokines when they recognize antigen in the infected tissue, some of which have the potential to inhibit the expression and replication of HBV in the hepatocyte. All limbs of the immune response must cooperate productively to terminate a viral infection. Individual differences in the efficiency of viral antigen processing by hepatocytes and professional antigen-presenting cells, or at the level of antigen recognition and responsiveness by B and T lymphocytes, will affect the strength of the antiviral immune response and the extent to which it contributes to viral clearance and liver disease. Finally, chronic hepatitis appears to be due to a sub-optimal cellular immune response that destroys some of the infected hepatocytes and does not purge the virus from the remaining infected hepatocytes, thereby permitting the persisting virus to trigger a chronic indolent necroinflammatory liver disease that sets the stage for development of HCC.
    American Journal Of Pathology 05/2000; 156(4):1117-32. · 4.59 Impact Factor
Show more

Preview (2 Sources)

77 Reads
Available from